Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis.
In the rapidly evolving field of neuroimaging, the convergence of engineering advancements and medical expertise is reshaping our approach to understanding and treating neurological disorders. This ...
Dallas steakhouse owner Al Biernat, whose charismatic presence at his namesake restaurant attracted both the famous and the ...
Clene (NASDAQ: CLNN) reported its Q3 2024 financial results and provided updates on its CNM-Au8 programs. Key operational highlights included a recent FDA meeting to discuss the potential for ...
After his ALS diagnosis, Zac Brown Band's John Driskell Hopkins plans to donate $3 million to fund research through his "Hop ...
Grammy winner John Driskell Hopkins, known as "Hop" from the Zac Brown Band, is turning his personal battle with amyotrophic ...
A funding boost of more than £78 million will help UCL scientists working to develop a potential treatment for motor neurone ...
Clene's cash, cash equivalents and marketable securities totaled $14.6 million as of September 30, 2024, compared to $35.0 million as of December 31, 2023. Clene expects that its resources as of ...